Literature DB >> 33260185

Pre-Stroke Glycemic Variability Estimated by Glycated Albumin Is Associated with Early Neurological Deterioration and Poor Functional Outcome in Prediabetic Patients with Acute Ischemic Stroke.

Sang-Hwa Lee1, Yerim Kim2, So Young Park3, Chulho Kim1, Yeo Jin Kim1, Jong-Hee Sohn4.   

Abstract

INTRODUCTION: Whether glycemic variability prior to stroke increases the risk of stroke outcomes in prediabetic patients presenting with acute ischemic stroke is still unclear. We evaluated whether pre-stroke glycemic variability, estimated by glycated albumin (GA), increased early neurological deterioration (END) and functional outcomes in prediabetic patients with acute ischemic stroke.
METHODS: A total of 215 acute ischemic stroke patients with prediabetes were evaluated. The primary outcome was END, defined as an incremental increase in the National Institutes of Health Stroke Scale score by ≥1 point in motor power or ≥2 points in the total score within the 7 days after admission. The secondary outcome was poor functional status defined by a modified Rankin Scale at 3 months. Higher GA (≥16.0%) was determined to reflect glycemic fluctuation prior to ischemic stroke.
RESULTS: Of the 215 prediabetic patients, 77 (35.8%) were in the higher GA group. In prediabetic patients, END occurrence and poor functional status were higher in the higher GA group than in the lower GA group. The multivariate analysis showed that a higher GA was associated with an increased risk of END occurrence and poor functional outcomes at 3 months (adjusted odds ratio [95% confidence interval], 4.58 [1.64-12.81], p = 0.004 and 2.50 [1.19-5.25], p = 0.02, respectively).
CONCLUSION: Pre-stroke glycemic variability estimated by GA was associated with END occurrence and poor functional outcome after ischemic stroke in patients with prediabetes.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  3-month functional outcome; Acute ischemic stroke; Early neurological deterioration; Glycated albumin; Prediabetes

Mesh:

Substances:

Year:  2020        PMID: 33260185     DOI: 10.1159/000511938

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

1.  Keap1-Nrf2/ARE signal pathway activated by butylphthalide in the treatment of ischemic stroke.

Authors:  Xiaofeng Zhang; Qiang Wu; Zhihui Wang; Haimei Li; Jie Dai
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 2.  A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke.

Authors:  Xiaotan Ji; Long Tian; Shumei Yao; Fengyue Han; Shenna Niu; Chuanqiang Qu
Journal:  Front Aging Neurosci       Date:  2022-05-30       Impact factor: 5.702

3.  High glycemic albumin representing prestroke glycemic variability is associated with hemorrhagic transformation in patients receiving intravenous thrombolysis.

Authors:  Sang-Hwa Lee; Min Uk Jang; Yerim Kim; So Young Park; Chulho Kim; Yeo Jin Kim; Jong-Hee Sohn
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

4.  Glycemic control is not related to cerebral small vessel disease in neurologically asymptomatic individuals with type 1 diabetes.

Authors:  Jussi Inkeri; Krishna Adeshara; Valma Harjutsalo; Carol Forsblom; Ron Liebkind; Turgut Tatlisumak; Lena M Thorn; Per-Henrik Groop; Sara Shams; Juha Martola; Jukka Putaala; Daniel Gordin
Journal:  Acta Diabetol       Date:  2021-11-15       Impact factor: 4.280

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.